Detalhe da pesquisa
1.
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Oncologist
; 28(12): e1152-e1159, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37555463
2.
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Breast
; 72: 103575, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690320
3.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404683
4.
Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
Anticancer Res
; 41(1): 485-496, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33419847
5.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Breast Care (Basel)
; 16(1): 50-58, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33716632
6.
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ther Adv Med Oncol
; 12: 1758835920973130, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33281950